#AS­CO21: EQRx's cheap­er EGFR drug busts Ires­sa in head-to-head test, and a US fil­ing could be right down the road

With a slew of pricey on­col­o­gy drugs dom­i­nat­ing the mar­ket, dis­rup­tor EQRx has pledged to launch its own dis­count­ed com­peti­tors to bring the fight to Big Phar­ma’s pock­et­book. One of EQRx’s hope­fuls, an EGFR in­hibitor, bust­ed one of As­traZeneca’s old-guard drugs in a head-to-head test, and those re­sults could put an even big­ger game in the biotech’s sights.

EQRx and Han­soh Phar­ma’s au­mol­er­tinib post­ed a pro­gres­sion-free sur­vival of 19.3 months in first-line, ad­vanced non-small cell lung can­cer pa­tients com­pared with 9.9 months for pa­tients on As­traZeneca’s TKI in­hibitor Ires­sa (gefi­tinib), ac­cord­ing to full da­ta from the Phase III AE­NEAS study set to pre­sent­ed in June at AS­CO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER